Answers are grounded in this paper and cite their sources.
The coronavirus disease (COVID-19) pandemic has highlighted the ability of scientists to quickly react to the immense challenge presented to the world. The orally available 3CL protease inhibitor S-217622 is currently progressing through clinical trials and its discovery via structure-based drug design, screening and optimization by Shionogi and Hokkaido University is presented here.
No takes yet. Share an insight, caveat, or question.
Joel D. A. Tyndall (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: